Tolerance by engaging antigen during cellular homeostasis

(

TEACH

)

ITN Protocol #:

ITN062ST

Branded Name:

TEACH

ClinicalTrials.Gov ID:

NCT03504241

Treatment Protocol #:

Therapeutic Area:

Transplantation

Current Status:

Follow-up

ITN Website Clinical Trial Recruiting Site Document Portal Location Study on ITN TrialShare

Summary:

Alemtuzumab, Costimulation Blockade and Sirolimus: A Tolerogenic Canvas for Donor Antigen Delivery via MSC

Clinical Operations Associate Director

Clinical Operations Manager

ITN Biologist

ITN Biostat

ITN Clinical Trial Physician

Rho Scientist

Study Personnel:

Protocol Chair

Allan Kirk, MD PhD allan.kirk@duke.edu

Work:

919-681-3445

Protocol Chair

Michele DesMarais mdesmarais@immunetolerance.org

Work:

415-353-4406

Protocol Chair

Allison Dias adias@immunetolerance.org

Work:

415-353-4415

Protocol Chair

Juliete Francisco Da Silva, PhD jsilva@immunetolerance.org

Work:

205-960-1065

Protocol Chair

Noha Lim, PhD nlim@immunetolerance.org

Work:

240-235-6151

Protocol Chair

Sindhu Chandran, MD schandran@immunetolerance.org

Work:

415-610-4284

Protocol Chair

Theresa Scocca, PhD

Work:

Admin Links

Shortcuts

ITN Documents

Links